Tumor Microenvironment Features May Predict Immunotherapy Response in Rare Cancers
The University of Texas MD Anderson Cancer Center
Phase 2 trial investigated the effectiveness of pembrolizumab (Keytruda) in rare cancers Overall responses were modest, but analysis showed new potential biomarkers beyond the current genomic markers of response These biomarkers could expand benefits of immunotherapy to patients who previously would not have been expected to respond A new study in Cell Reports Medicine from researchers at The University of Texas MD Anderson Cancer Center identified key features that may help predict which types